Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Thursday, Needham reiterated a Hold rating on Globus Medical (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an impressive revenue growth of 102% over the last twelve months, following the company’s announcement of an agreement to acquire Nevro Corp (NYSE:NVRO) for approximately $195 million in cash. The acquisition price is set at $5.85 per share. According to InvestingPro, the company maintains a "GREAT" financial health score of 3.28, suggesting strong operational stability.
Globus Medical, a medical device company currently trading near its 52-week high of $94.93, stated that the acquisition of Nevro, which is not currently rated, is expected to be completed towards the end of the second quarter of 2025. Nevro is known for its HFX spinal cord stimulation system, which is used to treat chronic back or leg pain, painful diabetic neuropathy, and non-surgical back pain, as well as the Nevro1 sacroiliac joint fusion system. InvestingPro subscribers have access to 14 additional key insights about Globus Medical’s growth potential and financial stability.
The transaction is anticipated to be roughly 6% dilutive to Globus Medical’s earnings per share (EPS) in 2025, which translates to a $0.20 impact at the mid-point. However, Globus Medical’s management is optimistic that Nevro will contribute positively to earnings in the second year following the closure of the deal.
Needham’s analyst pointed out that while there had been increasing confidence in Globus Medical due to their successful integration of another acquisition, the path to achieving accretive value from Nevro, while also maintaining its revenue growth, could present more of a challenge. As a result of these considerations, Needham has decided to maintain its Hold rating on Globus Medical shares.
In other recent news, Globus Medical has announced plans to acquire Nevro Corp., a medical device company, for approximately $250 million. The acquisition, which is expected to close in the second quarter of 2025, has led to a projected approximate 20 cents per share dilution in 2025, translating to about a 6% impact. However, Globus Medical anticipates accretion in the second year following the acquisition.
Analysts from Jefferies, BTIG, Stifel, and Canaccord Genuity have maintained their Buy ratings on Globus Medical, with price targets at $105, $91, $92, and $101 respectively. The acquisition is seen as a strategic move to expand Globus Medical’s portfolio and strengthen its position in the medical device sector.
Despite the initial skepticism from the market, the analysts have expressed confidence in Globus Medical’s ability to execute the acquisition and integrate Nevro’s operations. The acquisition is expected to be accretive to Globus Medical’s operating profit by fiscal year 2026, with Nevro potentially contributing between $35 million to $40 million in operating profit.
These developments follow Globus Medical’s announcement of preliminary 2024 sales of $2.52 billion, a 60.6% increase from the previous year. Post-acquisition, the company forecasts 2025 net sales of $2.80 billion to $2.90 billion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.